

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/013633 A2

(51) International Patent Classification⁷: **G01N 33/68**,
C07K 1/22, C07D 401/04, 239/72

(21) International Application Number:
PCT/EP2003/008375

(22) International Filing Date: 29 July 2003 (29.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02016840.7 29 July 2002 (29.07.2002) EP
02028880.9 23 December 2002 (23.12.2002) EP

(71) Applicant (for all designated States except US): **AXXIMA
PHARMACEUTICALS AG** [DE/DE]; Max-Leb-
sche-Platz 32, 81377 Munich (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GODL, Klaus**
[DE/DE]; Albrecht-Duerer-Strasse 18A, 82152 Krailling

(DE). **MISSIO, Andrea** [DE/DE]; Wuermtalerstr. 162A,
81375 Munich (DE). **DAUB, Henrik** [DE/DE]; Appen-
zeller Strasse 116, 81475 Munich (DE). **STEIN-GER-
LACH, Matthias** [DE/DE]; Vinzenz-Schuepfer-Strasse
30, 81475 Munich (DE). **GREFF, Zoltan** [HU/HU];
Gyöngyvirag u.8, H-1028 Budapest (HU).

(74) Agents: **LEIDESCHER, Thomas** et al.; Zimmermann &
Partner, Postfach 330 920, 80069 Munich (DE).


(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): **ARIPO** patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: MEDIUM AND METHOD FOR ENRICHING, PURIFYING OR DEPLETING ATP BINDING PROTEINS FROM A
POOL OF PROTEINS

In vitro kinase assay p38 α



(57) Abstract: The present invention relates to a medium and a method for enriching ATP binding proteins, e.g. protein kinases, from a pool of proteins, like a proteome. The medium of the present invention comprises specific inhibitors, e.g. at least one of the compounds 4-[4-(4-fluoro-phenyl)-5-pyridine-4-yl]-1H-imidazole-2-yl]-benzylamine, 2-[4-(2-Amino-ethoxy)-phenylamino]-6-(2,6-dichloro-phenyl)-8-methyl-8H-pyrido[2,3-d]pyrimidine-7-one, 2-[1-(3-aminopropyl)-1H-indole-3-yl]maleimide, 3-[1-(3-Aminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleinimide, 3-[1-(3-Aminopropyl)-1H-indol-3-yl]-4-(1-methyl-1H-indol-3-yl) maleinimide, 3-(8-Aminomethyl-6,7,8,9-tetrahydropyrido-[1,2-a]-indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-maleinimide, [6-(3-Amino-propoxy)-methoxy-quinazolin-4-yl]-(3-chloro-phenyl)-amine, 6-(3-Amino-propoxy)-7-methoxy-quinazolin-4-yl-(3-chloro-4-fluoro-phenyl)-amine, 6-(3-Amino-propoxy)-7-methoxy-quinazolin-4-yl-(3-bromo-phenyl)-amine and 4-[4-(4-Amino-butyl)-piperazin-1-yl-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide immobilized on a support material. According to the method of the present invention the above-mentioned immobilized compounds are used to selectively bind protein kinases from a pool of heterogeneous proteins.